CLAIMS

1. An isolated monoclonal antibody that binds to an epitope of human tissue factor pathway inhibitor (SEQ ID NO:1), wherein said epitope comprises Ile105 and Arg107, and further optionally comprises one or more residues selected from the group consisting of Glu100, Glu101, Asp102, Pro103, Gly104, Cys106, Gly108, Tyr109, Lys126, Gly128, Gly129, Cys130, Leu131, Gly132, and Asn133 of SEQ ID NO:1, wherein the antibody has any set of the following light and heavy chains:
   (1) light chain having the amino acid sequence of SEQ ID: NO 2 and heavy chain having the amino acid sequence of SEQ ID: NO 3.
   (2) light chain having the amino acid sequence of SEQ ID: NO 4 and heavy chain having the amino acid sequence of SEQ ID: NO 5.
   (3) light chain having the amino acid sequence of SEQ ID: NO 6 and heavy chain having the amino acid sequence of SEQ ID: NO 7.
   (4) light chain having the amino acid sequence of SEQ ID: NO 8 and heavy chain having the amino acid sequence of SEQ ID: NO 9.

2. A pharmaceutical composition comprising a therapeutically effective amount of the monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition comprising a therapeutically effective amount of at least two monoclonal antibodies of claim 1 and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of any of claims 2 to 3 for treating genetic or acquired deficiencies or defects in coagulation.

5. The pharmaceutical composition of claim 4 for treating hemophilia A, B or C.

6. The pharmaceutical composition of any of claims 2 to 3 for shortening bleeding time.

7. An isolated nucleic acid molecule encoding the isolated monoclonal antibody of claim 1 that binds to an epitope of human tissue factor pathway inhibitor (SEQ ID NO: 1) .